Who is sponsoring NCT04229706?

NCT04229706 is sponsored by Tasly Pharmaceutical Group Co., Ltd.

What drugs are being tested in NCT04229706?

Interventions in NCT04229706: High dose Xiang Ju Ru Pi Ning capsule, Low dose Xiang Ju Ru Pi Ning capsule, Xiang Ju Ru Pi Ning capsule placebo.

What condition does NCT04229706 study?

NCT04229706 studies Hyperplasia of Breast.

Is NCT04229706 still recruiting?

NCT04229706 is currently completed. Last updated 5 September 2024.

Last reviewed 2024-09-05 · How we verify

NCT04229706

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)

Completed Phase 2 Last updated 5 September 2024

What this trial tests

Phase 2 trial testing High dose Xiang Ju Ru Pi Ning capsule in Hyperplasia of Breast in 180 participants. Completed in 15 January 2022.

Timeline

31 December 2019

Primary endpoint
12 January 2022

15 January 2022

Quick facts

Lead sponsor	Tasly Pharmaceutical Group Co., Ltd
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	180
Start date	31 December 2019
Primary completion	12 January 2022
Estimated completion	15 January 2022
Sites	8 locations across China

Drugs / interventions tested

High dose Xiang Ju Ru Pi Ning capsule — full drug profile →
Low dose Xiang Ju Ru Pi Ning capsule — full drug profile →
Xiang Ju Ru Pi Ning capsule placebo — full drug profile →

Conditions studied

Hyperplasia of Breast — all drugs for Hyperplasia of Breast →

Sponsor

Tasly Pharmaceutical Group Co., Ltd — full company profile →

Who can join

Adults 18 to 50, female only, with Hyperplasia of Breast. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule in Hyperplastic disease of breast patients .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Tasly Pharmaceutical Group Co., Ltd trials

Trials by the same sponsor.

NCT07269769 — A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD · Phase 3 · not yet recruiting
NCT07485595 — A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression · Phase 2, PHASE3 · not yet recruiting
NCT07514065 — TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy · Phase 1 · recruiting
NCT07318818 — A Clinical Trial of P134 Cells in Recurrent Glioblastoma · Phase 1, PHASE2 · recruiting
NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04229706 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tasly Pharmaceutical Group Co., Ltd
Last refreshed: 5 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04229706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing